IR-MED's Journey: Innovations in Non-Invasive Healthcare Tech
Exciting Innovations in Non-Invasive Healthcare
IR-MED Inc. (OTCQB: IRME), a pioneer in noninvasive, AI-driven healthcare technology, continues to forge ahead with innovative solutions designed to address significant challenges within the healthcare industry. Our Chief Executive Officer, Mr. Ran Ziskind, is thrilled to share updates that highlight our ongoing efforts and remarkable progress.
Expansion of PressureSafe™ Usability Studies
Our flagship device, PressureSafe™, shows great promise in transforming pressure injury assessments. As we expand usability studies in the U.S., we see a potential market worth $1.7 billion domestically and $2.9 billion globally. Designed to provide skin-agnostic assessments of pressure injuries, PressureSafe™ aims to mitigate harm in a healthcare sector that desperately needs effective solutions.
Understanding PressureSafe™
Our commitment to a data-driven approach led us to conduct significant usability studies both in Israel and the U.S. Recently, our dedicated clinical and executive teams showcased PressureSafe™ at the National Pressure Injury Advisory Panel (NPIAP) conference. This event united healthcare leaders, practitioners, and scientists, reflecting strong interest in our advanced technology.
Innovative Clinical Study Results
Key clinical studies have yielded noteworthy findings. At Clalit Medical Centers in Israel, critical assessments of PressureSafe™ highlighted its Infrared Spectroscopy capabilities. The study demonstrated an impressive sensitivity of 89% and specificity of 90% in identifying Stage 1 pressure injuries and suspected deep tissue injuries.
In the U.S., investigations at Methodist hospitals are proving that PressureSafe™ can reliably assist in evaluating pressure injuries across diverse skin tones, establishing a 90% sensitivity rate in ongoing Phase 1 trials. These studies underscore how PressureSafe™ can enhance patient assessment across different demographics.
Introducing DiaSafe™: Tackling Diabetic Foot Ulcers
In addition to PressureSafe™, we are enthusiastic about the development of DiaSafe™, an innovative decision-support device aimed at diabetic foot ulcer assessments. With diabetic foot ulcers being a leading cause of amputations, DiaSafe™ will provide invaluable non-invasive optical readings of biomarkers for effective intervention.
Development Highlights of DiaSafe™
Our development of DiaSafe™ has progressed significantly, backed by a $1 million grant from the Israel Innovation Authority. We are currently seeking additional funding and are in discussions to commence clinical trials, promising exciting advancements in the field of diabetic care.
Strategic Growth and Nasdaq Uplisting Plans
As part of our strategic initiatives, we are pursuing an uplisting to the Nasdaq Stock Exchange. We believe this move will strengthen shareholder value and broaden our access to institutional investors. We look forward to sharing more about this journey as it unfolds.
Explore IR-MED Further
We encourage our stakeholders to learn more about our innovative products, clinical advancements, and the impact of our technologies. Our latest presentations and studies provide an in-depth look at how we are committed to transforming non-invasive skin assessment and enhancing healthcare outcomes.
Thank you for your continued support as IR-MED Inc. strives to redefine standards in healthcare technology.
Sincerely,
Ran Ziskind
CEO, IR-MED Inc.
Frequently Asked Questions
What is PressureSafe™?
PressureSafe™ is a noninvasive device designed for the assessment of pressure injuries, employing advanced infrared spectroscopy technology.
How does DiaSafe™ aim to help diabetic patients?
DiaSafe™ will assist in the real-time assessment of diabetic foot ulcers, focusing on early interventions to prevent severe outcomes.
What market potential do IR-MED's products have?
IR-MED's products target significant market opportunities, with PressureSafe™ alone addressing a $1.7 billion market in the U.S.
How is IR-MED supported in its research?
IR-MED receives grants from the Israel Innovation Authority, aiding in the development and clinical trials of its technologies.
What are the future plans for IR-MED?
IR-MED is working towards a Nasdaq uplisting and expanding its product pipeline to enhance healthcare solutions.
About The Author
Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
